Company intelligence / Profile preview
Promentis Pharmaceuticals, Inc.
Milwaukee, Wisconsin, United Statespromentispharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Promentis Pharmaceuticals has completed Phase 1 studies showing its lead compound SXC‑2023 to be safe and well-tolerated. The company has initiated multiple Phase 2 studies targeting trichotillomania and OCD. Early results indicate promise for treating impulse control disorders by modulating glutamatergic signaling via System x_c^-. There are no FDA-approved therapies for the initial indication of trichotillomania.
- Therapeutic areas
- Psychiatry
- Modalities
- small molecules (novel oral compounds)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Promentis Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Promentis Pharmaceuticals, Inc..